Research & Education

New Approaches to the Treatment of Recurrent Small Cell Lung Cancer

September 19, 2018 at 9:00PM EDT - Recording Available
 Dr. Lauren Byers  

Lauren Averett Byers, MD
Associate Professor
Department of Thoracic/Head and Neck Medical Oncology
MD Anderson Cancer Center
Houston Texas

 Ramaswamy Govindan, MD - Program Chair

Director, Section of Medical Oncology
Professor of Medicine
Anheuser-Busch Endowed Chair in Medical Oncology
Director, Section of Oncology
Washington University School of Medicine


Name of Reviewer(s): 

Govind Babu, MD:

No Relevant Financial/Commercial relationships to disclose.

Odd Terje Brunstugun, MD: Advisory Board: Novartis, MSD/Merck, BoehringerIngelheim, Ariad;Honoraria: AstraZeneca, Bristol-Myers Squibb, Roche, PierreFabre, Novartis, Pfizer, BoehringerIngelheim, MSD/Merck, Eli Lilly; Contracted/Support Research Grant: Roche, AstraZeneca, GSK/Novartis


Name of Planner(s): 


Carlos Ferreira-Nothing to Disclose

 Education Committee (Planners)

 Fredericco Cappuzzo, MD

No relevant Financial/Commercial Relationships to Disclosed

Name of Activity: 


New Approaches to the Treatment of Recurrent Small Cell Lung Cancer 

Date of Activity:


9/19/2018 9:00 PM EDT


COI Resolution: Ensure a balanced discussion of alternative. Do not use trade names. Do not refer to company names or logos. Do not recommend therapies.

“All planning committee members’, reviewers, planners and faculty et al. identified conflicts of interest pertaining to this activity were resolved prior to the activity.”

Speaker: Dr. Lauren Averett Byers, MD

Medivation, Inc. (Consulting); AstraZeneca Pharmaceuticals (Scientific Advisory Committee Member); AbbVie (Consulting); Lilly (Consulting)

Chair: Ramaswamy Govindan, MD

Pfizer: Advisory Board, Celgene: Advisory Board, AztraZeneca: Advisory Board, INC Research: Consulting, AbbVie: Consulting, Advisory Board and Honorarium, MSK: Advisory Board, BMS, ROCHE, ABBVIE, CELGENE, AZ, MERCK: Honoraria.

Type of Activity:

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?


If yes, please list:

Small cell lung cancer (SCLC) remains a challenging disease to treat, especially following relapse. However, new treatment options and potential biomarkers have emerged, including a role for immunotherapy in this disease.  In this presentation, Dr. Byers will provide a comprehensive review of the evolving landscape of SCLC treatment - with a focus on the management of patients with recurrent disease.


  • Identify and discuss recent data and current clinical research evaluating the efficacy and safety of immunotherapeutic agents in the treatment of recurrent SCLC.
  • Assess those clinical research findings that are most relevant to treating clinicians.
  • Appraise the utility of immunotherapy in the management of recurrent SCLC and its evolutionary role in current treatment algorithms.


After attending this webinar, learners will:

  • Provide a comprehensive review of the current treatment landscape for recurrent small cell lung cancer (SCLC).
  • Update scientific progress in the discovery and use of new biomarkers.
  • Appraise the clinical role for immunotherapy in the treatment of recurrent SCLC.
  • Discuss the incorporation of immunotherapy into treatment paradigms.
  • Identify ongoing clinical trials that are likely to impact patient care in the near future.

In order to receive CME credit, attendees must fill out a program evaluation.

Following the presentation, there will be ample time for discussion and a question/answer session. Attendees will be able to submit questions and comments to Dr. Byers and Dr. Govindan via internet chat.


Financial Commercial and Conflicts of Interest Disclosure Form

IASLC Guidelines For Individuals Planning and/or Presenting a IASLC CME Activity

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)


DEFINITION OF A COMMERCIAL INTEREST: commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.


Continuing medical education consists of educational activities which serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession. The content of CME is that body of knowledge and skills generally recognized and accepted by the profession as within the basic medical sciences, the discipline of clinical medicine, and the provision of health care to the public.

Financial/Commercial Relationships DISCLOSURES

A conflict of interest (COI) is created and exists when individuals in a position to control the content of CME (or their spouses/partners) have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells or distributes health care goods or services consumed by, or used on, patients that benefits the individual in any financial amount and therefore may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds) or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership and other activities for which remuneration is received or expected. 

This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME Department assures that the planners/reviewers/authors/faculty/peer reviewers et al. conflicts of interest were identified, reviewed and resolved fromall individuals involved in the development or able to influence and control the content of this CME activity. The IASLC CME Department assures that disclosure is given prior to an educational activity being delivered to learners. Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from all IASLC CME activity presentations.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Committee and/or an independent reviewer. COI will be evaluated by the IASLC Board of Directors for fair balance, scientific objectivity of studies utilized in this activity and patient care recommendations. The IASLC CME Department is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

The intent of this disclosure is not to prevent a speaker with a relevant financial or other relationship from making the presentation, but rather to identify and resolve any conflicts of interest that may control the content of the activity. It is also intended that any potential conflict be identified openly so that the listeners have a full disclosure of the facts and may form their own judgments about the presentation. It remains for the audience to determine whether the speaker’s interests or relationships may influence the presentation with regard to exposition or conclusion.

All other faculty/contributors et al. have reported no commercial affiliation associated with this conference or intent to reference off-label/unapproved uses of products or devices in their presentations.


IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.


Creators/presenters/planners et al. are not permitted to receive any direct remuneration or gifts or in-kind support from any commercial interest in relationship to this activity, nor should faculty be subject to direction from commercial interests regarding the content or delivery of their presentation.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Please complete the evaluation link provided to you after the activity. The certificate of credit will be ready for you to print or save for your records.

Attendees can now view IASLC Live webinars via their mobile device.  

Downloading of the Cisco WebEx Meetings app is required.

Once the app is installed on your device you will need to enter the event number for each session.

 Registration is required for all IASLC webinars.